Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation

Liver Transplantation

Volumn 19, Issue 10, 2013, Pages 1132-1141

  Musat, Alexandru I ^a   Pigott, Courtney M ^a   Ellis, Thomas M ^a   Agni, Rashmi M ^a   Leverson, Glen E ^a   Powell, Amy J ^a   Richards, Katelyn R ^a   D'Alessandro, Anthony M ^a   Lucey, Michael R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONOR SPECIFIC HLA I ANTIBODY; DONOR SPECIFIC HLA II ANTIBODY; HLA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; FLOW CYTOMETRY; GRAFT DYSFUNCTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL TIME;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; ANTIBODIES; BIOPSY; COMPLEMENT C4B; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; RISK; ROC CURVE; TIME FACTORS; TISSUE DONORS;

EID: 84884907035     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23707     Document Type: Article

References (36)

1. Claas FHJ,. HLA immunogenetics and transplantation. In:, Wilkes DS, Burlingham WJ, eds. Immunobiology of Organ Transplantation. New York, NY: Kluwer Academic/Plenum; 2004: 45-52.
2. Turgeon NA, Kirk AD, Iwakoshi NN,. Differential effects of donor-specific alloantibody. Transplant Rev (Orlando) 2009; 23: 25-33.
3. Colvin RB,. C4d in liver allografts: a sign of antibody-mediated rejection? Am J Transplant 2006; 6: 447-448.
4. Hübscher SG,. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012; 17: 280-286.
5. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
6. Takaya S, Jain A, Yagihashi A, Nakamura K, Kobayashi M, Takeuchi K, et al. Increased bile duct complications and/or chronic rejection in crossmatch positive human liver allografts. Transplant Proc 1999; 31: 2028-2031.
7. Katz SM, Kimball PM, Ozaki C, Monsour H, Clark J, Cavazos D, et al. Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Transplantation 1994; 57: 616-620.
8. Charco R, Vargas V, Balsells J, Lázaro JL, Murio E, Jaurrieta E, et al. Influence of anti-HLA antibodies and positive T-lymphocytotoxic crossmatch on survival and graft rejection in human liver transplantation. J Hepatol 1996; 24: 452-459.
9. Goggins WC, Fisher RA, Kimball PM, Wolfe L, Hill BE, Pietruszka TD, et al. The impact of a positive crossmatch upon outcome after liver transplantation. Transplantation 1996; 62: 1794-1798.
10. Bathgate AJ, McColl M, Garden OJ, Forsythe JL, Madhavan KK, Hayes PC,. The effect of a positive T-lymphocytotoxic crossmatch on hepatic allograft survival and rejection. Liver Transpl Surg 1998; 4: 280-284.
11. Doran TJ, Geczy AF, Painter D, McCaughan G, Sheil AG, Süsal C, Opelz G,. A large, single center investigation of the immunogenetic factors affecting liver transplantation. Transplantation 2000; 69: 1491-1498.
12. Bishara A, Brautbar C, Eid A, Scherman L, Ilan Y, Safadi R,. Is presensitization relevant to liver transplantation outcome? Hum Immunol 2002; 63: 742-750.
13. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
14. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
15. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
16. Abu-Elmagd KM, Wu G, Costa G, Lunz J, Martin L, Koritsky DA, et al. Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant 2012; 12: 3047-3060.
17. Gordon RD, Fung JJ, Markus B, Fox I, Iwatsuki S, Esquivel CO, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705-715.
18. Matinlauri IH, Höckerstedt KA, Isoniemi HM,. Equal overall rejection rate in pre-transplant flow-cytometric cross-match negative and positive adult recipients in liver transplantation. Clin Transplant 2005; 19: 626-631.
19. Donaldson PT, Thomson LJ, Heads A, Underhill JA, Vaughan RW, Rolando N, Williams R,. IgG donor-specific crossmatches are not associated with graft rejection or poor graft survival after liver transplantation. An assessment by cytotoxicity and flow cytometry. Transplantation 1995; 60: 1016-1023.
20. Muro M, Marin L, Miras M, Moya-Quiles R, Minguela A, Sánchez-Bueno F, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transplant Immunol 2005; 14: 91-97.
21. Fujita S, Rosen C, Reed A, Langham MR Jr, Howard RJ, Lauwers GY, Scornik JC,. Significance of preformed anti-donor antibodies in liver transplantation. Transplantation 1997; 63: 84-88.
22. Lunz J, Ruppert KM, Cajaiba MM, Isse K, Bentlejewski CA, Minervini M, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171-182.
23. Ruiz R, Tomiyama K, Campsen J, Goldstein RM, Levy MF, McKenna GJ, et al. Implications of a positive crossmatch in liver transplantation: a 20-year review. Liver Transpl 2012; 18: 455-460.
24. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
25. Bartlett AS, Ramadas R, Furness S, Gane E, McCall JL,. The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl 2002; 8: 1147-1153.
26. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25: 658-663.
27. Watson R, Kozlowski T, Nickeleit V, Woosley JT, Schmitz JL, Zacks SL, et al. Isolated donor specific alloantibody-mediated rejection after ABO compatible liver transplantation. Am J Transplant 2006; 6: 3022-3029.
28. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK,. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
29. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
30. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
31. Singh N, Djamali A, Lorentzen D, Pirsch JD, Leverson G, Neidlinger N, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079-1084.
32. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
33. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
34. Girnita A, Mazariegos GV, Castellaneta A, Reyes J, Bentlejewski C, Thomson AW, Zeevi A,. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2010; 71: 274-276.
35. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18: 1333-1342.
36. Banff Working Group on Liver Allograft Pathology. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18: 1154-1170.